Intérêt d'un traitement par omalizumab dans le cadre d'une immunothérapie spécifique. Recueil d'expérience et analyse de la littérature The interest of treatment with omalizumab in the framework of specific immunotherapy J.-P. Oster a, * ,F. Lavaud b , A. Bentaleb c , Y. Bloch d , J.-L. Bourrain e , P. Carré f , G. Devouassoux g ,

Our aim was to assess the eventual impact of pretreatment with omalizumab on the tolerance and efficacy of specific immunotherapy (SIT). Based on a collection of experiences, we report observations on 10 groups of patients who have received that therapeutic combination. Six of these observations involved patients sensitized to bees; their SIT was stopped because of problems with tolerance. In these six observations, different sorts of pretreatment with omalizumab was considered effective, which allowed bee venom SIT to be started and then maintained. While no randomized clinical trial has evaluated the effect of omalizumab treatment on tolerance to hymenoptera venoms, a number of published reports